Paper
TL1A as a therapeutic target in inflammatory bowel disease
Published May 4, 2022 · G. Kokkotis, G. Bamias
Expert Review of Clinical Immunology
10
Citations
2
Influential Citations
Abstract
Tumor necrosis factor (TNF) and TNF-receptor (TNFR) superfamilies of proteins (TNFSF and TNFRSF, respectively) consist of several molecules with critical participation in a vast array of biological processes, including a pivotal role in the development and function of the immune system. TNF-like cytokine 1A (TL1A) that is encoded by the TNFSF15 gene was first described in 2002 [1]. The product is a type II transmembrane protein, which may exist in either membrane-bound or soluble forms, which are both functional but may exert diverse immunological effects. TL1A signals via binding to its functional receptor, death domain receptor 3 (DR3 or TNFFRSFf25), which shares the highest homology to TNFR1 among all members of the TNFRSF [2]. During the two decades that followed its original report, the TL1A/DR3 system of cytokines has arisen as an important module for mucosal immunity that is involved in the preservation of intestinal homeostasis but also critically participates in the development and maintenance of chronic inflammatory responses that take place in patients with inflammatory bowel diseases (IBD) [2].
TL1A is a promising therapeutic target for inflammatory bowel disease (IBD) due to its role in maintaining intestinal homeostasis and its potential role in chronic inflammation.
Full text analysis coming soon...